Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basis Second quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%...
Related Questions
How does the reported diluted EPS of $0.77 compare to consensus estimates and to the performance of peer companies in the orthopaedic device sector?
Will the earnings beat (if any) trigger short‑term buying pressure, and what technical patterns should traders monitor following the release?
Are there any macro‑economic or currency factors that could have materially impacted the constant‑currency results, and how might they evolve in the coming quarters?
How might the Q2 results influence ZBH's dividend policy or share repurchase plans, and what implications does that have for total return expectations?
What is the outlook for the second half of 2025—does management project continued sales acceleration, and what are the key risks (e.g., supply chain constraints, regulatory approvals, or competitive pressure)?
What drivers contributed to the adjusted diluted EPS of $2.07 and is the 3.0% increase reflective of margin improvement or one‑off items?
What is the significance of the 5.4% constant‑currency sales growth compared to the 2.8% organic growth, and does it indicate a sustainable sales trend?
How will the 7.0% increase in net sales versus the prior quarter affect ZBH's valuation multiples?
Will the sales growth and earnings results prompt any changes in analyst earnings forecasts or target prices for ZBH?
How does ZBH's second‑quarter performance stack up against its main competitors (e.g., Stryker, Medtronic, and Johnson & Johnson) in terms of revenue growth and profitability?